SynthesisFrontiers in medicine2026
Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of tumor treating fields (TTF) combined with chemotherapy compared with chemotherapy alone in patients with newly diagnosed and recurrent glioblastoma (GBM). Method: A systematic search was conducted in PubMed, Embase, Web of Science, Cochrane Library, and databases from their inception to 10 December 2025. Randomized controlled trials, controlled clinical trials and observational cohort studies evaluating the efficacy and safety of TTF in GBM treatment were included. Evaluating the efficacy and safety of TTF in GBM treatment were included. Data were pooled using Stata 15 software. Results: A total of 14 studies involving 2,376 patients (both newly diagnosed and recurrent GBM) were included: 7 RCTs, 4 CCTs, and 3 observational cohort studies were included. Pooled analyses demonstrated that compared with chemotherapy alone, TTF combined with chemotherapy significantly prolonged progression-free survival (PFS) (HR = 0.62, 95% CI: 0.55-0.69, Conclusion: In newly diagnosed and recurrent GBM, TTF combined with chemotherapy significantly improves survival outcomes compared with chemotherapy alone, highlighting the therapeutic value and safety of the combined treatment in both patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.